Richard Francis

Richard Francis, Teva's President and CEO, discusses his transformative journey at the helm. Over two and a half years, he has driven a 'Pivot to Growth' strategy, navigating challenges to achieve nine quarters of growth. Francis highlights Teva's innovative medicines like Austedo and Ajovy aimed at unmet medical needs, while also addressing the importance of expanding generics and biosimilars internationally. With a focus on modernization and a $700 million cost reduction, he shares insights into fostering long-term growth and staying committed to patient care.

Richard Francis, the President and CEO of Teva Pharmaceuticals, dives into the company's impressive shift toward branded medications, highlighting a notable 33% growth in that sector. He discusses how this strategy, contrasted with a decline in generics, led to a quarterly revenue surprise of $4.48 billion. Richard also covers ongoing pricing negotiations for Austedo and the challenges faced in the active pharmaceutical ingredients sale process, providing insights into Teva's future trajectory in the biopharma landscape.